title: A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma.
abstract: Glioblastoma is the most malignant tumor and has high mortality rate. The methylated prompter of MGMT results in chemotherapy sensitivity for these patients. However, there are still other factors that affected the prognosis for the glioblastoma patients with similar MGMT methylation status. We developed a signature with three genes screened from the whole genome mRNA expression profile from Chinese Glioma Genome Atlas (CGGA) and RNAseq data from The Cancer Genome Atlas (TCGA). Patients with MGMT methylation in low risk group had longer survival than those in high risk group (median overall survival 1074 vs. 372 days; P = 0.0033). Moreover, the prognostic value of the signature was significant difference in cohorts stratified by MGMT methylation and chemotherapy (P=0.0473), while there is no significant difference between low and high risk group or unmethylated MGMT patients without chemotherapy. Multivariate analysis indicated that the risk score was an independent prognosis factor (P = 0.004). In conclusion, our results showed that the signature has prognostic value for patients with MGMT promoter-methylated glioblastomas based on bioinformatics analysis.
authors: Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.|Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.|Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.|Chinese Glioma Cooperative Group (CGCG), Beijing, China.
authors: Wen
authors: W
authors: Wang
authors: Department of Ophthalmology, School of Medicine, Shandong University, Jinan, China.
authors: Lu
authors: L
authors: Zhang
authors: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.|Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.|Chinese Glioma Cooperative Group (CGCG), Beijing, China.
authors: Zheng
authors: Z
authors: Wang
authors: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.|Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.|Chinese Glioma Cooperative Group (CGCG), Beijing, China.
authors: Fan
authors: F
authors: Yang
authors: Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China.|Chinese Glioma Cooperative Group (CGCG), Beijing, China.
authors: Haoyuan
authors: H
authors: Wang
authors: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.|Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.|Chinese Glioma Cooperative Group (CGCG), Beijing, China.
authors: Tingyu
authors: T
authors: Liang
authors: Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.|Brain Tumor Center, Beijing Institute for Brain Disorders, Beijing, China.|Chinese Glioma Cooperative Group (CGCG), Beijing, China.
authors: Fan
authors: F
authors: Wu
authors: Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
authors: Qing
authors: Q
authors: Lan
authors: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.|Brain Tumor Center, Beijing Institute for Brain Disorders, Beijing, China.|Chinese Glioma Cooperative Group (CGCG), Beijing, China.
authors: Jiangfei
authors: J
authors: Wang
authors: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.|Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.|China National Clinical Research Center for Neurological Diseases, Beijing, China.
authors: Jizong
authors: J
authors: Zhao
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000401:mortality*; D019175:DNA Methylation; D015254:DNA Modification Methylases / Q000235:genetics*; D045643:DNA Repair Enzymes / Q000235:genetics*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy / Q000235:genetics / Q000401:mortality*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011401:Promoter Regions, Genetic; D016016:Proportional Hazards Models; D025521:Tumor Suppressor Proteins / Q000235:genetics*
chemical_list: D025521:Tumor Suppressor Proteins; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes
keywords: MGMT; RNA-Seq; glioblastoma; prognosis; signature